Our Company

We are a biopharmaceutical company on a mission to develop treatments for serious diseases.

Our current portfolio includes novel clinical-stage assets, as well as multiple research stage molecules. Concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Leveraging a Critical Pathway

Cyclerion was founded with the goal of unlocking the full therapeutic potential of the nitric oxide-cyclic guanosine monophosphate (cGMP) signaling pathway.  Our portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator with potential in cardiovascular diseases. The nitric oxide (NO) – soluble guanylate cyclase (sGC) – cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body.

Startup Spirit, Mature Biotech Expertise

Founded in 2019, Cyclerion is an independent, publicly traded company. Our mission is to develop innovative medicines for patients in desperate need of new treatment options. We pursue this mission with the emboldened spirit, passionate culture, and drive of a startup, while bolstered by the expertise and leadership of a mature biotech. 

Value-Creating Enablers

Our strategy to deliver impact to patients and create value for stockholders rests on a solid scientific foundation that is enabled by our people and capabilities, external collaborators, and a responsive capital allocation approach.

Value Enablers

Drug-hunting experience

Our board has diverse experience identifying, developing and gaining regulatory approval for novel assets.

We leverage a diverse cross-disciplinary network of external advisors and experts to advance our programs. We do this by:

  1. Engaging leading experts to access additional technologies and expertise to advance our programs
  2. Establishing advisory boards of physicians, patients and payors to provide insights into the unmet medical need and to support the design of clinical trials
  3. Consulting scientific advisory boards made up of veteran drug hunters with broad industry experience and a track record of innovation

We will apply a ‘‘best-owner’’ approach to our compounds whereby we develop and commercialize product candidates independently or through a partner depending on which path we believe will accelerate global patient access to our drugs and offer the greatest risk-adjusted value for our stockholders.

To inquire about partnering with Cyclerion, please reach out to us at partnering@cyclerion.com.

The capital allocation decision making and financial management we use in our business is designed to enable us to continually deploy capital to the most promising opportunities.


Regina Graul, PhD

Board of Directors

Errol De Souza, PhD, Chair Peter Hecht, PhD Michael Higgins Steven Hyman, MD Dina Katabi, PhD  Terrance McGuire

Contact Us

Cyclerion Therapeutics
245 First Street
Riverview II, 18th Floor
Cambridge, MA 02142

Phone: 857-327-8778
Email: info@cyclerion.com
Fax: 617-890-6595

Investor Relations or Media Inquiries: IR@cyclerion.com
Partnering Inquiries: partnering@cyclerion.com
Sponsorship Inquiries: sponsorships@cyclerion.com